These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 26231106)

  • 1. Formulation and process factors influencing product quality and in vitro performance of ophthalmic ointments.
    Xu X; Al-Ghabeish M; Rahman Z; Krishnaiah YS; Yerlikaya F; Yang Y; Manda P; Hunt RL; Khan MA
    Int J Pharm; 2015 Sep; 493(1-2):412-25. PubMed ID: 26231106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of drug loading and type of ointment base on the in vitro performance of acyclovir ophthalmic ointment.
    Al-Ghabeish M; Xu X; Krishnaiah YS; Rahman Z; Yang Y; Khan MA
    Int J Pharm; 2015 Nov; 495(2):783-91. PubMed ID: 26343911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation characteristics and in vitro release testing of cyclosporine ophthalmic ointments.
    Dong Y; Qu H; Pavurala N; Wang J; Sekar V; Martinez MN; Fahmy R; Ashraf M; Cruz CN; Xu X
    Int J Pharm; 2018 Jun; 544(1):254-264. PubMed ID: 29684560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of active pharmaceutical ingredient variables and oleaginous base on the in vitro drug release from ophthalmic ointments: An investigation using dexamethasone as a model drug.
    Mekjaruskul C; O'Reilly Beringhs A; Qin B; Wang Y; Lu X
    Int J Pharm; 2024 Jun; 658():124184. PubMed ID: 38692497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and ex vivo correlation of drug release from ophthalmic ointments.
    Bao Q; Newman B; Wang Y; Choi S; Burgess DJ
    J Control Release; 2018 Apr; 276():93-101. PubMed ID: 29518465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspectives on Physicochemical and In Vitro Profiling of Ophthalmic Ointments.
    Bao Q; Burgess DJ
    Pharm Res; 2018 Oct; 35(12):234. PubMed ID: 30324424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physicochemical attributes and dissolution testing of ophthalmic ointments.
    Bao Q; Jog R; Shen J; Newman B; Wang Y; Choi S; Burgess DJ
    Int J Pharm; 2017 May; 523(1):310-319. PubMed ID: 28344172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterization of sponge-like acyclovir ocular minitablets.
    Refai H; Tag R
    Drug Deliv; 2011 Jan; 18(1):38-45. PubMed ID: 20804440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of performance matrix for generic product equivalence of acyclovir topical creams.
    Krishnaiah YS; Xu X; Rahman Z; Yang Y; Katragadda U; Lionberger R; Peters JR; Uhl K; Khan MA
    Int J Pharm; 2014 Nov; 475(1-2):110-22. PubMed ID: 25089511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality by design approach for understanding the critical quality attributes of cyclosporine ophthalmic emulsion.
    Rahman Z; Xu X; Katragadda U; Krishnaiah YS; Yu L; Khan MA
    Mol Pharm; 2014 Mar; 11(3):787-99. PubMed ID: 24423028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro release testing method development for ophthalmic ointments.
    Bao Q; Shen J; Jog R; Zhang C; Newman B; Wang Y; Choi S; Burgess DJ
    Int J Pharm; 2017 Jun; 526(1-2):145-156. PubMed ID: 28461266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Manufacturing Process Variables on the Properties of Ophthalmic Ointments of Tobramycin.
    Patere S; Newman B; Wang Y; Choi S; Vora S; Ma AWK; Jay M; Lu X
    Pharm Res; 2018 Jul; 35(9):179. PubMed ID: 30046909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting the particle size distribution and rheology of brinzolamide ophthalmic suspensions.
    Vo A; Feng X; Patel D; Mohammad A; Kozak D; Choi S; Ashraf M; Xu X
    Int J Pharm; 2020 Aug; 586():119495. PubMed ID: 32553495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluplus micelles for acyclovir ocular delivery: Formulation and cornea and sclera permeability.
    Varela-Garcia A; Concheiro A; Alvarez-Lorenzo C
    Int J Pharm; 2018 Dec; 552(1-2):39-47. PubMed ID: 30253214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro transcorneal permeation of ketorolac from oil based ocular drops and ophthalmic ointment.
    Malhotra M; Majumdar DK
    Indian J Exp Biol; 1997 Dec; 35(12):1324-30. PubMed ID: 9567769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of in vitro release methods on assessment of tobramycin ophthalmic ointments.
    Patere S; Newman B; Wang Y; Choi S; Mekjaruskul C; Jay M; Lu X
    Int J Pharm; 2020 Nov; 590():119938. PubMed ID: 33011250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of drug release from ointments: Role of transient-boundary layer.
    Xu X; Al-Ghabeish M; Krishnaiah YS; Rahman Z; Khan MA
    Int J Pharm; 2015 Oct; 494(1):31-9. PubMed ID: 26241753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of tolnaftate release from fatty acids containing ointment and penetration into human skin ex vivo.
    Kezutyte T; Drevinskas T; Maruska A; Rimdeika R; Briedis V
    Acta Pol Pharm; 2011; 68(6):965-73. PubMed ID: 22125963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an Ointment Formulation Using Hot-Melt Extrusion Technology.
    Bhagurkar AM; Angamuthu M; Patil H; Tiwari RV; Maurya A; Hashemnejad SM; Kundu S; Murthy SN; Repka MA
    AAPS PharmSciTech; 2016 Feb; 17(1):158-66. PubMed ID: 26628438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioadhesive microspheres for ophthalmic administration of acyclovir.
    Genta I; Conti B; Perugini P; Pavanetto F; Spadaro A; Puglisi G
    J Pharm Pharmacol; 1997 Aug; 49(8):737-42. PubMed ID: 9379347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.